For patients with T2D uncontrolled on oral antidiabetic drugs (OADs) or glucagon-like peptide 1 receptor agonists (GLP-1RAs), the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) guidelines recommend the use of basal insulin as an alternative option [14]. This evidence concerns the gene INS and diabetes mellitus.